172 related articles for article (PubMed ID: 8453188)
21. Bicalutamide in advanced prostate cancer. A review.
Goa KL; Spencer CM
Drugs Aging; 1998 May; 12(5):401-22. PubMed ID: 9606617
[TBL] [Abstract][Full Text] [Related]
22. Provocation test coupled with bronchoalveolar lavage in diagnosis of drug (nilutamide)-induced hypersensitivity pneumonitis.
Akoun GM; Liote HA; Liote F; Gauthier-Rahman S; Kuntz D
Chest; 1990 Feb; 97(2):495-8. PubMed ID: 2298082
[TBL] [Abstract][Full Text] [Related]
23. Nilutamide approved for metastatic prostate cancer.
Am J Health Syst Pharm; 1996 Dec; 53(23):2784. PubMed ID: 8957341
[No Abstract] [Full Text] [Related]
24. A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma.
Béland G; Elhilali M; Fradet Y; Laroche B; Ramsey EW; Trachtenberg J; Venner PM; Tewari HD
Cancer; 1990 Sep; 66(5 Suppl):1074-9. PubMed ID: 2203517
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
[TBL] [Abstract][Full Text] [Related]
26. Antiandrogen withdrawal syndrome with nilutamide.
Huan SD; Gerridzen RG; Yau JC; Stewart DJ
Urology; 1997 Apr; 49(4):632-4. PubMed ID: 9111642
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of the pure non-steroidal antiandrogen nilutamide in prostatic cancer. Italian Prostatic Cancer Project (PONCAP).
Decensi A; Guarneri D; Paoletti MC; Lalanne JM; Merlo F; Boccardo F
Eur J Cancer; 1991; 27(9):1100-4. PubMed ID: 1835617
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of basal and adrenocorticotropin-stimulated plasma levels of adrenal androgens after treatment with an antiandrogen in castrated patients with prostatic cancer.
Bélanger A; Dupont A; Labrie F
J Clin Endocrinol Metab; 1984 Sep; 59(3):422-6. PubMed ID: 6086697
[TBL] [Abstract][Full Text] [Related]
29. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
Fiet J; Doré JC; Gô AL; Ojasoo T; Raynaud JP
Prostate; 1993; 23(4):291-313. PubMed ID: 8259343
[TBL] [Abstract][Full Text] [Related]
30. Anandron (nilutamide) combined with orchiectomy in stage D prostate cancer patients. Overview of seven randomized placebo controlled studies.
Hucher M; de Gery A; Bertagna C
Cancer; 1993 Dec; 72(12 Suppl):3886-7. PubMed ID: 8252510
[No Abstract] [Full Text] [Related]
31. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
[TBL] [Abstract][Full Text] [Related]
32. Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer.
Eastham JA; Sartor O
J Urol; 1998 Mar; 159(3):990. PubMed ID: 9474206
[No Abstract] [Full Text] [Related]
33. Stimulation of erythropoiesis by the non-steroidal anti-androgen nilutamide in men with prostate cancer: evidence for an agonistic effect?
Decensi A; Torrisi R; Fontana V
Br J Cancer; 1994 Mar; 69(3):617-9. PubMed ID: 8123500
[TBL] [Abstract][Full Text] [Related]
34. Improved subjective responses to orchiectomy plus nilutamide (anandron) in comparison to orchiectomy plus placebo in metastatic prostate cancer. International Anandron Study Group.
Dijkman GA; Fernandez del Moral P; Debruyne FM; Janknegt RA
Eur Urol; 1995; 27(3):196-201. PubMed ID: 7601182
[TBL] [Abstract][Full Text] [Related]
35. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
[TBL] [Abstract][Full Text] [Related]
36. [Nilutamide-induced acute hepatitis].
Hammel P; Ducreux M; Bismuth E; Ladouch-Badre A; Benoit G; Buffet C; Etienne JP
Gastroenterol Clin Biol; 1991; 15(6-7):557. PubMed ID: 1916139
[No Abstract] [Full Text] [Related]
37. Pharmacological and clinical studies of the antiandrogen Anandron.
Moguilewsky M; Bertagna C; Hucher M
J Steroid Biochem; 1987; 27(4-6):871-5. PubMed ID: 3320565
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics and metabolism of nilutamide.
Creaven PJ; Pendyala L; Tremblay D
Urology; 1991; 37(2 Suppl):13-9. PubMed ID: 1992598
[TBL] [Abstract][Full Text] [Related]
39. A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.
Davis NB; Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 Oct; 96(6):787-90. PubMed ID: 16153201
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of Deuterium Labeled 5, 5-Dimethyl-3-(α, α, α-trifluoro-4-nitro-m-tolyl) Hydantoin.
Bolla RS; Gandikota NM; Kasi Viswanath IV
Curr Radiopharm; 2019; 12(1):82-87. PubMed ID: 30854946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
